,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Ms. Linda F. Powers J.D.', 'age': 66, 'title': 'Chairperson, CEO, Pres, CFO & Chief Accounting Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 1100000, 'exercisedValue': 0, 'unexercisedValue': 43327644}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
1,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Dr. Alton L. Boynton Ph.D.', 'age': 77, 'title': 'Founder, Chief Scientific Officer, Sec. & Director', 'yearBorn': 1945, 'fiscalYear': 2022, 'totalPay': 450000, 'exercisedValue': 0, 'unexercisedValue': 4597314}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
2,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Dr. Marnix L. Bosch M.B.A., MBA, Ph.D.', 'age': 63, 'title': 'Chief Technical Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 597500, 'exercisedValue': 0, 'unexercisedValue': 16162125}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
3,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Mr. Leslie J. Goldman', 'age': 77, 'title': 'Sr. VP & Gen. Counsel', 'yearBorn': 1945, 'fiscalYear': 2022, 'totalPay': 825000, 'exercisedValue': 0, 'unexercisedValue': 27374524}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
4,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Ms. Jean M. Davis', 'age': 50, 'title': 'Chief Information Officer', 'yearBorn': 1972, 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
5,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Mr. David  Innes', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
6,4800 Montgomery Lane,Suite 800,Bethesda,MD,20814,United States,240 497 9024,https://www.nwbio.com,Biotechnology,Healthcare,"Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",22,"{'maxAge': 1, 'name': 'Mr. Pankaj R. Shah C.A., CPA', 'title': 'Financial Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.6922,0.7,0.68,0.7,0.6922,0.7,0.68,0.7,0.0,-0.146611,1768702,1768702,1759380,2124840,2124840,0.0,0.0,0,0,769614528,0.4,1.27,408.50027,0.5534,0.6408,0.0,0.0,USD,824334208,0.0,1036934596,1121069952,14142788,13831447,1477872000,1480464000,0.113400005,0.11038999,0.00307,13.54,0.1509,-0.055,1672444800,1703980800,1688083200,-87164000,-0.07,1:16,1348617600,437.545,-13.966,PNK,EQUITY,NWBO,NWBO,NORTHWEST BIOTHERAPEUTICS INC,"Northwest Biotherapeutics, Inc.",1008340200,America/New_York,EDT,-14400000,0.6865,none,1424000,0.001,-59024000,30758000,0.036,0.116,1884000,0.002,-1.3477901,-33828000,-94075376,-47727000,-0.579,0.0,0.0,-32.026012,USD,
